Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function.

Front Immunol · 2022 · PMC9174989 · PMID 35693794

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Consistently, immunostaining with anti-E-cadherin or ZO-1 antibodies revealed that tegoprazan markedly increased the adhesion and tight junction protein production in the Caco-2 monolayer; conversely, rabeprazole displayed a decreasing trend in these proteins ( Figure 3F ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.